why did bioc stock drop so much from 2014

Is Bioc stock a good buy?

The consensus among 2 Wall Street analysts covering (NASDAQ: BIOC) stock is to Strong Buy BIOC stock.

Will Bioc reverse split?

Biocept's common shares will continue to trade under the ticker symbol "BIOC." Authorization for the reverse stock split was approved by the Company's stockholders at Biocept's 2020 Annual Meeting of Stockholders.

Will biocept stock recover?

If you are looking for stocks with good return, Biocept Inc can be a profitable investment option. Biocept Inc quote is equal to 0.855 USD at 2022-06-27. Based on our forecasts, a long-term increase is expected, the "BIOC" stock price prognosis for 2027-06-25 is 4.007 USD.

Shares of the small molecular diagnostics specialist took a beating after it announced an infrequently used method to raise cash

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights

What happened

Shares of small molecular diagnostics company Biocept, Inc. ( NASDAQ:BIOC) are plummeting today, down 21.5% as of 11:53 a.m. EDT, following its announcement of a proposed rights offering. The decline marked a quick change of direction after Biocept's share price more than doubled on Wednesday.

So what

If all this sounds complicated, it's because it is pretty complicated. Rights offerings are one of several ways for companies to raise cash. However, they're not used as nearly as frequently as stock offerings. A key advantage of a rights offering compared to a stock offering is that it doesn't cause dilution of the value in existing shares.

Now what

Current Biocept shareholders will have to soon decide what to do with their subscription rights. They can exercise them, which means shelling out more money to buy Biocept preferred stock. The other option is to let the rights expire. Which step should be taken depends on your view of the company's prospects.